Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/med.21379 http://scihub22266oqcxt.onion/10.1002/med.21379 C4752390!4752390 !26395559     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26395559 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Med+Res+Rev 2016 ; 36 (2 ): 313-41 Nephropedia Template TP {{tp|p=26395559 |t=2016. Direct Activation of Bax Protein for Cancer Therapy |pdf=|usr=}}{{26395559 }} gab.com Text Direct Activation of Bax Protein for Cancer Therapy JO: Med Res Rev http://www.kidney.de/pget.php?&tw=1&pmid=26395559 #FOAvip Bax, a central cell death regulator, is an indispensable gateway to mitochondrial dysfunction and a major proapoptotic member of the B-cell lymphoma 2 (Bcl-2) family proteins that control apoptosis in normal and cancer cells. Dysfunction of apoptosis renders the cancer cell resistant to treatment as well as promotes tumorigenesis. Bax activation induces mitochondrial membrane permeabilization, thereby leading to the release of apoptotic factor cytochrome c and consequently cancer cell death. A number of drugs in clinical use are known to indirectly activate Bax. Intriguingly, recent efforts demonstrate that Bax can serve as a promising direct target for small-molecule drug discovery. Several direct Bax activators have been identified to hold promise for cancer therapy with the advantages of specificity and the potential of overcoming chemo- and radioresistance. Further investigation of this new class of drug candidates will be needed to advance them into the clinic as a novel means to treat cancer. Twit Text FOAVip Direct Activation of Bax Protein for Cancer Therapy ????Med Res Rev http://www.kidney.de/pget.php?&tw=1&pmid=26395559 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26395559 #FOAvip English Wikipedia <ref>{{Cite pmid|26395559 }}</ref> Direct Activation of Bax Protein for Cancer Therapy #MMPMID26395559 Liu Z ; Ding Y ; Ye N ; Wild C ; Chen H ; Zhou J Med Res Rev 2016[Mar]; 36 (2 ): 313-41 PMID26395559 show ga Bax, a central cell death regulator, is an indispensable gateway to mitochondrial dysfunction and a major proapoptotic member of the B-cell lymphoma 2 (Bcl-2) family proteins that control apoptosis in normal and cancer cells. Dysfunction of apoptosis renders the cancer cell resistant to treatment as well as promotes tumorigenesis. Bax activation induces mitochondrial membrane permeabilization, thereby leading to the release of apoptotic factor cytochrome c and consequently cancer cell death. A number of drugs in clinical use are known to indirectly activate Bax. Intriguingly, recent efforts demonstrate that Bax can serve as a promising direct target for small-molecule drug discovery. Several direct Bax activators have been identified to hold promise for cancer therapy with the advantages of specificity and the potential of overcoming chemo- and radioresistance. Further investigation of this new class of drug candidates will be needed to advance them into the clinic as a novel means to treat cancer. |Amino Acid Sequence [MESH] |Animals [MESH] |Humans [MESH] |Models, Biological [MESH] |Molecular Sequence Data [MESH] |Neoplasms/*metabolism/*therapy [MESH] |Signal Transduction/drug effects [MESH] |Small Molecule Libraries/chemistry/pharmacology [MESH]Direct Activation of Bax Protein for Cancer Therapy (epmc).pdf DeepDyve Pubget Overpricing